Peripheral blood TCR marker for breast cancer and detection kit and application thereof

A marker and breast cancer technology, applied in the field of genetic engineering, can solve the problems of inconsistent HER-2 positive standards and large fluctuations in the inconsistency rate

Pending Publication Date: 2020-10-23
CHENGDU EXAB BIOTECH CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that human epidermal growth factor receptor-2 (HER-2) can be used as an evaluation indicator for breast cancer prognosis, but the inconsistent rate of HER-2 status in CTC and histology fluctuates greatly, and the HER-2 positive status of CTC Different standards

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker for breast cancer and detection kit and application thereof
  • Peripheral blood TCR marker for breast cancer and detection kit and application thereof
  • Peripheral blood TCR marker for breast cancer and detection kit and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1: Obtaining a breast cancer TCR marker CDR3 sequence set by immunographic analysis

[0072] 1. Sampling and immune map analysis

[0073] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people for model building, 1 healthy person for verification), 21 breast cancer patients (20 people for model building, 1 person for verification) and the peripheral blood of a subject with unknown health status (10mL per person), and the amino acid sequence of the TCR epitope 3 (CDR3) of the subject and the control group was obtained by high-throughput sequencing to ensure the functionality of each sample The total number of CDR3 sequences of TCR should not be less than 30,000;

[0074] 2. The CDR3 sequence of the TCR of each sample is randomly sampled without replacement, so that the total number of CDR3 sequences of each sample is 30,000. For any specific CDR3 sequence X, the number of repeated occurrences in the single-sample...

Embodiment 2

[0080] Example 2: Verification of the specificity of the breast cancer TCR marker CDR3 sequence set

[0081] 1. Sampling and immune map analysis

[0082]Peripheral blood (10 mL per person) was collected from 328 non-breast cancer tumor patients and 2 subjects with unknown health status, and the epitope 3 (CDR3) amino acids of the TCR of the subjects and the control group were obtained by high-throughput sequencing Sequences, to ensure that the total number of CDR3 sequences of functional TCRs in each sample is not less than 30,000; random non-replacement sampling is performed on the CDR3 sequences of TCRs in each sample, so that the total number of CDR3 sequences in each sample is 30,000.

[0083] 2. Randomly select 100 healthy people and 45 non-tumor disease patients from the control group in Example 1.

[0084] 3. According to 100 healthy people, 45 non-tumor disease patients, 20 breast cancer patients from embodiment 1, and 328 non-breast cancer tumor patients and 2 unknow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a peripheral blood TCR (T cell receptor) marker for breast cancer and a detection kit and an application thereof. The marker comprises at least one of proteins shown as SEQ IDNO.1-100 in sequence. The method is based on a high-throughput sequencing method, only a small amount of peripheral blood needs to be collected, the method comprises the following steps of extractingRNA (Ribonucleic Acid), treating a sample to establish an immune map database, carrying out high-throughput sequencing and TCR data analysis, firstly determining a characteristic TCR sequence in peripheral blood of breast cancer, and then comparing a test result of a sample to be tested with the characteristic TCR sequence so as to determine whether the patient suffers from breast cancer or not. The marker can simultaneously compare a huge number of breast cancer specific TCR sequences, has higher specificity and accuracy compared with single detection of one or more markers, and improves diagnosis efficiency.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a peripheral blood TCR marker of breast cancer, a detection kit and application thereof. Background technique [0002] Breast cancer is the most common malignant tumor in women worldwide, and it is also one of the leading causes of cancer death in adult women. Its incidence rate accounts for 23% of all tumors, and its mortality rate ranks second among all cancers. According to the latest statistics, there are approximately 2.088 million new breast cancer patients and approximately 627,000 breast cancer deaths in the world every year, and nearly 60% of the new breast cancer cases occur in developed countries. In developed countries, the number of new cases of breast cancer is about 25% of all malignant tumors, and the incidence rate is 79.09 / 100,000. In developing countries, the number of new cases of breast cancer is about 15.89% of all malignant tumors. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574
CPCG01N33/57415G01N33/57488
Inventor 张志新杨鑫卓越钟雪梅刘小银
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap